Meme Kanserinin Nadir Histolojik Alt Tipleri ve Nüks Eden Meme Kanseri

WHO Classification of Tumours Editorial Board. Breast Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2019.

Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):66.

McCart Reed AE, Kalaw E, Nones K, et al. Phenotypic and molecular dissection of special histological types of breast cancer. J Pathol. 2019;249(2):229-238.

Memiş A, Özdemir N, Parıltar M, et al. Mucinous (colloid) breast carcinoma: mammographic and sonographic features with histologic correlation. Eur J Radiol. 2000;35(1):39-42.

Meyer JE, Amin E, Lindfors KK, et al. Medullary carcinoma of the breast: mammographic and sonographic appearance. Radiology. 1989;170(1 Pt 1):79-82.

Dhillon R, DePree P, Metcalf C, et al. Imaging features of mucinous carcinoma of the breast: correlation with histopathology. Clin Radiol. 2006;61(5):423-429.

Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology. 2002;34(4):309-314.

Vu-Nishino H, Tavassoli FA, Ahrens WA, Haffty BG. Clinicopathologic features and long-term outcomes of patients with medullary breast carcinoma managed with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2005;62(4):1040-1047.

Günhan-Bilgen I, Memiş A, Üstün EE, et al. Metaplastic carcinoma of the breast: clinical, mammographic, and sonographic findings with histopathologic correlation. AJR Am J Roentgenol. 2002;178(6):1421-1425.

Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2(5):367-376.

Hoda RS, Brogi E, Pareja F, et al. Secretory carcinoma of the breast: clinicopathologic profile of 14 cases highlighting its metastatic potential. Histopathology. 2019;75(2):213-221.

Vo T, Xing Y, Meric-Bernstam F, et al. Long-term outcomes of mucinous, medullary, tubular, and invasive ductal carcinoma after lumpectomy. J Am Coll Surg. 2007;205(5):527-534.

Sullivan T, Raad RA, Goldberg S, et al. Tubular carcinoma of the breast: retrospective review and analysis of literature. Breast Cancer Res Treat. 2005;93(2):199-204.

El-Tamer MB, Troxel A, et al. Pure tubular carcinoma of the breast: a comparison with infiltrating ductal carcinoma. J Am Coll Surg. 199(5):657-661.

Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long-term follow-up of 11,400 pure mucinous breast carcinomas. Breast Cancer Res Treat. 2008;111(3):541-547.

Rakha EA, Lee AH, Evans AJ, et al. Tubular carcinoma of the breast: further evidence supporting its excellent prognosis. J Clin Oncol. 2010;28(1):99-104.

Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(5):331-357.

Huober J, Gelber S, Goldhirsch A, et al. Prognosis of medullary breast cancer: regional analysis of the International Breast Cancer Study Group trials. Ann Oncol. 2012;23(11):2843-2851.

Ridolfi RL, Rosen PP, Port A, Kinne D, Miké V. Medullary carcinoma of the breast: a clinicopathologic study with 10-year follow-up. Cancer. 1977;40(4):1365-1385.

Page DL. Adenoid cystic carcinoma of the breast: a special histopathologic type with excellent prognosis. Breast Cancer Res Treat. 2005;93(2):189-195.

Ghabach B, Anderson WF, Curtis RE, et al. Adenoid cystic carcinoma of the breast in the United States (1977-2006): a population-based cohort study. Breast Cancer Res. 2010;12(4):R54.

Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378(8):731-739.

Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21(2):271-282.

Vranic S, Marchiò C, Castellano I, et al. Immunohistochemical and molecular profile of histologically defined apocrine carcinomas of the breast. Hum Pathol. 2015;46(9):1350-1359.

Dellapasqua S, Maisonneuve P, Viale G, et al. Immunohistochemically defined subtypes and outcome of apocrine breast cancer. Clin Breast Cancer. 2013;13(2):95-102.

Verras GI, Tchabashvili L, Mulita F, et al. Micropapillary breast carcinoma: from molecular pathogenesis to prognosis. Breast Cancer (Dove Med Press). 2022;14:41-49.

Wang S, Zhang Y, Yin F, et al. Survival outcomes after breast-conserving therapy compared with mastectomy in patients with early-stage invasive micropapillary carcinoma of the breast: a SEER population-based study. Front Oncol. 2021;11:741737.

Hao S, Zhao YY, Peng JJ, et al. Invasive micropapillary carcinoma of the breast had no difference in prognosis compared with invasive ductal carcinoma: a propensity-matched analysis. Sci Rep. 2019;9(1):286.

Martinez EO, Jorns JM, Kong AL, et al. Primary breast neuroendocrine tumors: an analysis of the National Cancer Database. Ann Surg Oncol. 2022;29(10):6339-6348.

Angarita FA, Rodríguez JL, Meek E, et al. Locally advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature. World J Surg Oncol. 2013;11:128.

Yildirim Y, Elagöz S, Koyuncu A, et al. Management of neuroendocrine carcinomas of the breast: a rare entity. Oncol Lett. 2011;2(5):887-890.

Bae SY, Lee SK, Koo MY, et al. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat. 2011;126(2):471-478.

Wong W, Brogi E, Reis-Filho JS, et al. Poor response to neoadjuvant chemotherapy in metaplastic breast carcinoma. NPJ Breast Cancer. 2021;7(1):96.

Al-Hilli Z, Choong G, Keeney MG, et al. Metaplastic breast cancer has a poor response to neoadjuvant systemic therapy. Breast Cancer Res Treat. 2019;176(3):709-716.

Yam C, Abuhadra N, Sun R, et al. Molecular characterization and prospective evaluation of pathologic response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res. 2022;28(13):2878-2887.

Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556-567.

Cortes J, Cescon DW, Rugo HS, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817-1828.

Joneja U, Vranic S, Swensen J, et al. Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1. J Clin Pathol. 2017;70(3):255-259.

Kim I, Rajamanickam V, Bernard B, et al. A case series of metastatic metaplastic breast carcinoma treated with anti-PD-1 therapy. Front Oncol. 2021;11:635237.

Adams S, Othus M, Patel SP, et al. A multicenter phase II study of ipilimumab and nivolumab in rare tumors (DART SWOG S1609), cohort 36: dual CTLA-4 and PD-1 blockade in metastatic metaplastic breast cancer. Clin Cancer Res. 2022;28(2):271-279.

Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159-182.

Amir E, Clemons M, Purdie CA, et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of two large prospective studies. J Clin Oncol. 2012;30(6):587-592.

Wapnir IL, Anderson SJ, Mamounas EP, et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol. 2006;24(13):2028-2037.

Buchholz TA, Ali S, Hunt KK. Multidisciplinary management of locoregional recurrent breast cancer. J Clin Oncol. 2020;38(20):2321-2330.

Aebi S, Gelber S, Anderson SJ, et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014;15(2):156-163.

Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(5):331-357.

Loibl S, André F, Bachelot T, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159-182.

Khatcheressian JL, Hurley P, Bantug E, et al. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2013;31(7):961-965.